重组干扰素-β（IFN-β ser）在弥漫性间皮瘤患者中的II期评估：一项西南肿瘤协作组的研究
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
作者信息
Von Hoff D D, Metch B, Lucas J G, Balcerzak S P, Grunberg S M, Rivkin S E
机构信息
University of Texas Health Science Center, San Antonio 78284.
出版信息
J Interferon Res. 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531.
Fourteen evaluable patients with diffuse malignant mesothelioma were treated with a once-a-day for 5 days out of 7 for 6 weeks regimen of recombinant interferon-beta (IFN-beta ser). No responses were noted. The major toxicities included fever, chills, nausea, vomiting, and anorexia. IFN-beta ser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma.
14例可评估的弥漫性恶性间皮瘤患者接受了重组干扰素-β（IFN-β ser）治疗，治疗方案为每周7天中5天每天一次，共6周。未观察到缓解情况。主要毒性包括发热、寒战、恶心、呕吐和厌食。按此剂量和疗程使用的IFN-β ser对难治性恶性间皮瘤患者似乎不是一种有效的单一药物。
Zotero 插件